# Tinostamustine and Nivolumab in Advanced Melanoma

> **NCT03903458** · PHASE1 · UNKNOWN · sponsor: **Markus Joerger** · enrollment: 21 (estimated)

## Conditions studied

- Malignant Melanoma

## Interventions

- **DRUG:** Tinostamustine

## Key facts

- **NCT ID:** NCT03903458
- **Lead sponsor:** Markus Joerger
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-03-07
- **Primary completion:** 2021-12-15
- **Final completion:** 2024-03-15
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2019-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03903458

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03903458, "Tinostamustine and Nivolumab in Advanced Melanoma". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03903458. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*